Three device trials returned null results in one week and the strongest positive readings came from a sham comparison that failed
The week
Cardiology dominated the week and most of it went against the devices. A sham-controlled trial of atrial fibrillation ablation, a national trial of targeted lead placement, and a transcatheter valve anticoagulation study all reported results that make existing practice harder to defend rather than easier. The clearest positive signals came from a lipid-lowering mortality analysis and a phase 3 in HER2-positive breast cancer.
Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF): a randomised, double-blind, sham-controlled, multicentre trial
The Lancet · sham-controlled randomised trial · · devices · confidence medium
Market Sensitivity Score 79/100
Evidence16
Exposure17
Catalyst12
Novelty19
Attention15
What the paper showed
Among 262 patients randomised to catheter ablation or a sham procedure, the between-group difference in six-month change in AFEQT quality-of-life score was 2.6 points (95% CI -2.7 to 8.0; p=0.36). Procedure-related serious adverse events occurred in six patients in the ablation group and four in the sham group.
Why it scores where it does
Atrial fibrillation ablation has been sold on symptom relief, and this is the first double-blind sham-controlled test of that claim to report a null result. Both arms improved substantially, from 61.3 to 81.1 in the ablation group and 59.2 to 74.9 in the sham group, which locates most of the observed benefit in the placebo response rather than in pulmonary vein isolation. The trial enrolled 262 of 1199 invited patients and measured quality of life at six months, so it speaks to symptom benefit rather than to stroke or mortality endpoints, and twelve-month follow-up is still open.
What would resolve it
Twelve-month follow-up from the same cohort, which the investigators state is ongoing, and any revision to the atrial fibrillation ablation guidelines that cites it.
Linked companies · benchmark IHI
BSXBoston ScientificNYSEsupplier · high exposure
JNJJohnson & JohnsonNYSEsupplier · medium exposure
MDTMedtronicNYSEsupplier · medium exposure
ABTAbbott LaboratoriesNYSEsupplier · medium exposure
Among 521 patients with ERBB2-positive breast cancer, the total pathological complete response rate was 62.4 percent with anbenitamab plus HB1801 versus 51.2 percent in the control group, an absolute difference of 11.4 percentage points (95% CI 3.2 to 19.6; P=.004). Benefit was consistent across hormone receptor-positive and hormone receptor-negative subgroups.
Why it scores where it does
Anbenitamab is a HER2 bispecific antibody and the lead clinical asset of its sponsor, so a phase 3 neoadjuvant trial meeting its primary endpoint concentrates a large share of that company's value in one readout. The 11.4 point absolute pathological complete response difference is a conventional regulatory endpoint in this setting and the confidence interval excludes no effect. Pathological complete response is a surrogate, event-free and overall survival are not yet reported, and the trial was conducted in a single national regulatory environment.
What would resolve it
The National Medical Products Administration decision on the anbenitamab new drug application, which the sponsor has said was accepted for review.
Linked companies · benchmark XBI
9966Alphamab OncologyHKEXsponsor · high exposure
1093CSPC Pharmaceutical GroupHKEXpartner · medium exposure
Addition of Computed Tomography-derived Fractional Flow Reserve in the diagnostic pathway of patients with stable coronary artery disease: the FUSION trial
Journal of the American College of Cardiology · randomised trial · · diagnostics · confidence medium
Market Sensitivity Score 74/100
Evidence15
Exposure19
Catalyst13
Novelty14
Attention13
What the paper showed
Among 528 patients randomised to an FFRct-guided pathway or usual care, invasive coronary angiography without obstructive disease occurred in 18 percent versus 33 percent at 90 days (odds ratio 0.46; 95% CI 0.31 to 0.69; P<0.001). Revascularisation rates were 20 percent in both groups at one year.
Why it scores where it does
CT-derived fractional flow reserve is the entire commercial premise of its principal vendor, which listed publicly in 2025, so randomised evidence that it halves unnecessary invasive angiography speaks directly to that company's reimbursement case. The effect persisted at one year and the absolute reduction of fifteen percentage points is large enough to matter to payers who fund the downstream catheterisation. Revascularisation rates, quality of life and costs did not differ, so the argument is about avoided procedures rather than better outcomes, and clinical event rates were low.
What would resolve it
Coverage and reimbursement decisions for CT-derived fractional flow reserve, and the vendor's first full-year results as a public company.
Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial
Circulation · prespecified analysis of a phase 3 RCT · · pharma · confidence high
Market Sensitivity Score 70/100
Evidence19
Exposure12
Catalyst13
Novelty16
Attention10
What the paper showed
Among 12,257 patients followed a median of 4.6 years, all-cause mortality was 20 percent lower with evolocumab than placebo, 434 deaths versus 539 (hazard ratio 0.80; 95% CI 0.70 to 0.91; P=0.0005). Cardiovascular death occurred in 156 patients versus 195 (hazard ratio 0.79; 95% CI 0.64 to 0.98).
Why it scores where it does
No PCSK9 inhibitor had previously shown an all-cause mortality reduction, and this one does so in patients without prior myocardial infarction or stroke, which is a far larger population than the secondary prevention setting where the class is currently concentrated. The analysis was prespecified within a 12,257-patient double-blind trial and the mortality signal is directionally consistent across cardiovascular, non-cardiovascular and undetermined causes. The sponsor employs several of the authors, the headline trial result was already public, and this is a component analysis rather than a new trial.
What would resolve it
Guideline treatment thresholds for primary prevention lipid lowering, and any label discussion arising from the mortality data.
Stent Retriever Thrombectomy in Patients With Myocardial Infarction: The Open-label, Multicenter NATURE Superiority trial
Journal of the American College of Cardiology · randomised superiority trial · · devices · confidence medium
Market Sensitivity Score 63/100
Evidence13
Exposure12
Catalyst9
Novelty16
Attention13
What the paper showed
Infarct size measured by CK-MB area under the curve was lower with stent-retriever thrombectomy before conventional PCI than with conventional PCI alone, 3965 versus 5250 IU/L·h (difference -1359; 95% CI -2231 to -522; p=0.001) across 154 patients. On cardiac magnetic resonance, infarct size was 17 percent of the left ventricle versus 28 percent.
Why it scores where it does
Stent retrievers are neurovascular devices with an established stroke market, and a randomised infarct-size benefit in myocardial infarction opens a second and much larger indication for hardware that already exists and is already manufactured. The effect on the primary biomarker endpoint was significant and the imaging substudy pointed the same way. The trial enrolled 154 patients, the endpoint is a surrogate rather than a clinical outcome, ventricular volumes and ejection fraction did not differ, and event counts were too small to interpret.
What would resolve it
Whether a clinical-endpoint trial is registered in this indication, and any interventional cardiology guideline commentary.
Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: The NOTION-4 Trial
Journal of the American College of Cardiology · randomised trial · · devices · confidence medium
Market Sensitivity Score 61/100
Evidence15
Exposure11
Catalyst10
Novelty13
Attention12
What the paper showed
Among 347 analysed patients, hypo-attenuated leaflet thickening at three months occurred in 12.1 percent of those given three months of a direct oral anticoagulant versus 31.8 percent given single antiplatelet therapy. The combined risk of death, stroke or major bleeding at twelve months was 8.2 percent with anticoagulation versus 2.3 percent with antiplatelet therapy.
Why it scores where it does
Subclinical leaflet thrombosis has been an unresolved durability question hanging over transcatheter aortic valves, and this trial shows it can be suppressed pharmacologically but at a bleeding cost that exceeds the imaging benefit. The leaflet finding was large at three months and the safety difference ran the other way, which makes routine anticoagulation after valve implantation harder rather than easier to justify. The effect had attenuated by nine months after the drug stopped, and the trial was not powered for clinical endpoints.
What would resolve it
Whether valve durability registries report any long-term signal tied to leaflet thickening, and antithrombotic guidance for transcatheter aortic valve replacement.
Linked companies · benchmark IHI
EWEdwards LifesciencesNYSEsupplier · medium exposure
Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial
Nature Medicine · phase 3 RCT · · oncology · confidence high
Market Sensitivity Score 61/100
Evidence17
Exposure9
Catalyst10
Novelty14
Attention11
What the paper showed
Adding atezolizumab to neoadjuvant chemotherapy in stage II-III triple-negative breast cancer did not significantly improve event-free survival across 1550 randomised patients, with a hazard ratio of 0.80 and a stratified log-rank P of 0.083. Immune-related adverse events were reported in 27.6 percent of the atezolizumab group versus 11.4 percent of the placebo group.
Why it scores where it does
This is a second phase 3 failure for atezolizumab in early triple-negative breast cancer, in a setting where a competing PD-1 antibody already holds the indication, and it removes the main remaining path for the sponsor to contest that position. The trial randomised 1550 patients and missed its primary endpoint despite a hazard ratio pointing the right way, with a four-year event-free survival difference of 3.3 percent. Prespecified subgroup analysis suggested benefit in patients with clinical lymph node involvement, so a biomarker-defined path is not formally closed.
What would resolve it
Whether the sponsor pursues a biomarker-selected trial in node-positive disease, and competitor share commentary at the next quarterly results.
Targeted left ventricular lead placement in biventricular pacing for heart failure: a national, multicentre, double-blind, randomised controlled trial in Denmark
The Lancet · randomised controlled trial · · devices · confidence medium
Market Sensitivity Score 58/100
Evidence16
Exposure9
Catalyst8
Novelty13
Attention12
What the paper showed
Among 1000 patients analysed, death or unplanned heart failure hospitalisation occurred in 139 of 499 patients assigned targeted left ventricular lead placement versus 128 of 501 assigned conventional placement (hazard ratio 1.10; 95% CI 0.86 to 1.39; p=0.45). Lead-related complications were more frequent in the intervention group.
Why it scores where it does
Imaging-guided lead placement is the premise behind several mapping and planning features that cardiac resynchronisation vendors position as premium, and a 1000-patient double-blind trial finding no benefit weakens the case for paying for them. Median follow-up was 45.8 months, so this is a durable negative rather than an underpowered one, and the intervention arm carried more lead-related complications. It tests lead siting rather than resynchronisation itself, so the underlying device category is unaffected.
What would resolve it
Whether cardiac resynchronisation guidelines retain any recommendation for targeted lead placement at the next revision.
Among 261 children with relapsed or refractory B-cell acute lymphoblastic leukaemia, 259 achieved complete remission with negative minimal residual disease. Event-free survival was 70.9 percent at twelve months and 61.7 percent at thirty-six months.
Why it scores where it does
Dual-target CAR T-cell therapy is the leading answer to CD19 antigen escape, which is the main mechanism by which the approved single-target products fail, and a 261-patient series reaching 99 percent complete remission is the largest evidence yet that the approach holds at scale. Three-year event-free survival of 61.7 percent sets a bar that single-target products have not matched in this population. The trial was nonrandomised, consolidative transplant was associated with markedly better outcomes and confounds the comparison, and no commercial sponsor is attached to the construct.
What would resolve it
Whether any commercial developer licenses a bicistronic CD19/CD22 construct, and competing dual-target readouts at the December haematology meetings.
In cohort A, AZD5462 20 mg produced a placebo-adjusted change in end-systolic volume index of -5.4 mL/m2 at week 25 (95% CI -10.9 to 0.1; P=0.054), narrowly missing significance across 235 randomised participants. In cohort B, 140 participants showed significant placebo-adjusted reductions in systemic vascular resistance index at all doses.
Why it scores where it does
Relaxin biology has failed repeatedly in heart failure, most prominently in acute decompensation, so an oral agonist reaching a near-significant remodelling signal in chronic disease is the first result in years that keeps the mechanism alive. The haemodynamic endpoints moved consistently across doses in the second cohort and the drug was tolerated on top of good background therapy. The primary endpoint was missed at P=0.054, the endpoints are imaging and haemodynamic rather than clinical, and the sponsor is large enough that one phase 2b asset moves little.
What would resolve it
Whether the sponsor commits to a phase 3 programme, which the authors say larger and longer trials are needed to justify.
Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study
Updated follow-up confirms longer progression-free survival with genomic profiling, but the primary analysis was already published and the sponsor is too large for the readout to concentrate.
Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial
The rapid troponin pathway met non-inferiority for safety across 67,624 presentations but did not shorten emergency department stay, so the assay makers gain no throughput argument.
Vericiguat for the treatment of coronary vasospasm (ViVA): a double-blind placebo-controlled randomized cross-over trial
A negative crossover trial in 57 patients, too small and too far from the drug's approved indication to carry exposure.
How the score works
The Market Sensitivity Score is the sum of five components, each scored 0 to 20. It measures how likely a paper is to matter to a listed company, not whether the company is worth owning. The full method is here.
Evidence
design, N, endpoint, effect size, journal
Exposure
how concentrated the company value is
Catalyst
how near the next resolving event is
Novelty
distance from current consensus
Attention
how little is already priced in
Sources checked: PubMed; NEJM; The Lancet; JAMA and JAMA Oncology; Nature Medicine; Nature Biotechnology; Journal of Clinical Oncology; Circulation; Journal of the American College of Cardiology; Science Translational Medicine; Company disclosures on sponsor identity.